Prato
Prato
Prato, Tuscany, Italy6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance | Disease Attributes, Embolism, Embolism and Thrombosis, Emergencies, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, Ventricular Dysfunction, Ventricular Dysfunction, Right, cardiac arrest, cardiovascular disorder, chronic thromboembolic pulmonary hypertension, heart disorder, lung disorder, pulmonary embolism, respiratory system disorder, vascular disorder, venous thromboembolism | Recruiting | Not stated | 2026-10-07 | NCT07855679 | |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | HER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT05132582 | |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-23 | NCT07085767 | |
| To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-09-14 | NCT04660435 | |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-08-10 | NCT06926868 | |
| A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-03 | NCT02246621 |